Stockreport

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma [Yaho...

Citius Pharmaceuticals, Inc.  (CTXR) 
NASDAQ:AMEX Investor Relations: ir.citiuspharma.com
PDF CRANFORD, N.J. Feb. 13, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated t [Read more]